Arthur Allen

The Market for Biosimilars Is Funky. The Industry Thinks PBMs Are To Blame

KFF Health News Original

Over the past year there’s been movement to rein in the three big PBMs, which face little regulation though they help set drug prices and drug choices for 80 percent of Americans and their doctors. The House voted Dec. 11, 320-71, for legislation that would require the PBMs to change some of the ways they […]